Attention Allocation During Exploration of Visual Arrays in ASD: Results from the ABC-CT Feasibility Study / Tawny TSANG in Journal of Autism and Developmental Disorders, 53-8 (August 2023)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 53-8 (August 2023) . - p.3220-3229 Titre : Attention Allocation During Exploration of Visual Arrays in ASD: Results from the ABC-CT Feasibility Study Type de document : texte imprimé Auteurs : Tawny TSANG, Auteur ; Adam J. NAPLES, Auteur ; Erin C. BARNEY, Auteur ; Minhang XIE, Auteur ; Raphael A. BERNIER, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali S. JESTE, Auteur ; James C. MCPARTLAND, Auteur ; Charles A. NELSON, Auteur ; Michael MURIAS, Auteur ; Helen SEOW, Auteur ; Catherine SUGAR, Auteur ; Sara J. WEBB, Auteur ; Frederick SHIC, Auteur ; Scott JOHNSON, Auteur Article en page(s) : p.3220-3229 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Visual exploration paradigms involving object arrays have been used to examine salience of social stimuli such as faces in ASD. Recent work suggests performance on these paradigms may associate with clinical features of ASD. We evaluate metrics from a visual exploration paradigm in 4-to-11-year-old children with ASD (n 23; 18 males) and typical development (TD; n 23; 13 males). Presented with arrays containing faces and nonsocial stimuli, children with ASD looked less at (p 0.002) and showed fewer fixations to (p 0.022) faces than TD children, and spent less time looking at each object on average (p 0.004). Attention to the screen and faces correlated positively with social and cognitive skills in the ASD group (ps < .05). This work furthers our understanding of objective measures of visual exploration in ASD and its potential for quantifying features of ASD. En ligne : https://doi.org/10.1007/s10803-022-05569-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=508 [article] Attention Allocation During Exploration of Visual Arrays in ASD: Results from the ABC-CT Feasibility Study [texte imprimé] / Tawny TSANG, Auteur ; Adam J. NAPLES, Auteur ; Erin C. BARNEY, Auteur ; Minhang XIE, Auteur ; Raphael A. BERNIER, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali S. JESTE, Auteur ; James C. MCPARTLAND, Auteur ; Charles A. NELSON, Auteur ; Michael MURIAS, Auteur ; Helen SEOW, Auteur ; Catherine SUGAR, Auteur ; Sara J. WEBB, Auteur ; Frederick SHIC, Auteur ; Scott JOHNSON, Auteur . - p.3220-3229. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 53-8 (August 2023) . - p.3220-3229 Index. décimale : PER Périodiques Résumé : Visual exploration paradigms involving object arrays have been used to examine salience of social stimuli such as faces in ASD. Recent work suggests performance on these paradigms may associate with clinical features of ASD. We evaluate metrics from a visual exploration paradigm in 4-to-11-year-old children with ASD (n 23; 18 males) and typical development (TD; n 23; 13 males). Presented with arrays containing faces and nonsocial stimuli, children with ASD looked less at (p 0.002) and showed fewer fixations to (p 0.022) faces than TD children, and spent less time looking at each object on average (p 0.004). Attention to the screen and faces correlated positively with social and cognitive skills in the ASD group (ps < .05). This work furthers our understanding of objective measures of visual exploration in ASD and its potential for quantifying features of ASD. En ligne : https://doi.org/10.1007/s10803-022-05569-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=508

Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials / Lawrence SCAHILL in Journal of Autism and Developmental Disorders, 43-3 (March 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-3 (March 2013) . - p.739-746 Titre : Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials Type de document : texte imprimé Auteurs : Lawrence SCAHILL, Auteur ; Victoria HALLETT, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; L. Eugene ARNOLD, Auteur ; James T. MCCRACKEN, Auteur ; Elaine TIERNEY, Auteur ; Yanhong DENG, Auteur ; James DZIURA, Auteur ; Benedetto VITIELLO, Auteur Article en page(s) : p.739-746 Langues : Anglais (eng) Mots-clés : Social disability  Autism  Research Units on Pediatric Psychopharmacology (RUPP)  Autism Network  Social withdrawal  Risperidone  Aberrant Behavior Checklist Index. décimale : PER Périodiques Résumé : There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials. En ligne : http://dx.doi.org/10.1007/s10803-012-1689-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=192 [article] Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials [texte imprimé] / Lawrence SCAHILL, Auteur ; Victoria HALLETT, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; L. Eugene ARNOLD, Auteur ; James T. MCCRACKEN, Auteur ; Elaine TIERNEY, Auteur ; Yanhong DENG, Auteur ; James DZIURA, Auteur ; Benedetto VITIELLO, Auteur . - p.739-746. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-3 (March 2013) . - p.739-746 Mots-clés : Social disability  Autism  Research Units on Pediatric Psychopharmacology (RUPP)  Autism Network  Social withdrawal  Risperidone  Aberrant Behavior Checklist Index. décimale : PER Périodiques Résumé : There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials. En ligne : http://dx.doi.org/10.1007/s10803-012-1689-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=192

Clinician-caregiver informant discrepancy is associated with sex, diagnosis age, and intervention use among autistic children / Margaret A. AZU in Autism, 29-3 (March 2025)  

Public ISBD [article]  inAutism > 29-3 (March 2025) . - p.614-626 Titre : Clinician-caregiver informant discrepancy is associated with sex, diagnosis age, and intervention use among autistic children Type de document : texte imprimé Auteurs : Margaret A. AZU, Auteur ; Gloria T. HAN, Auteur ; Julie M. WOLF, Auteur ; Adam J. NAPLES, Auteur ; Katarzyna CHAWARSKA, Auteur ; Geraldine DAWSON, Auteur ; Raphael A. BERNIER, Auteur ; Shafali S. JESTE, Auteur ; James DZIURA, Auteur ; Sara J. WEBB, Auteur ; Catherine A. SUGAR, Auteur ; Frederick SHIC, Auteur ; James C. MCPARTLAND, Auteur Article en page(s) : p.614-626 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Clinician and caregiver reports of autism features are both integral to receiving an autism diagnosis and appropriate intervention, yet informant discrepancies are present in clinical practice and may differ by demographic characteristics of the child and ... En ligne : https://dx.doi.org/10.1177/13623613241279999 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=550 [article] Clinician-caregiver informant discrepancy is associated with sex, diagnosis age, and intervention use among autistic children [texte imprimé] / Margaret A. AZU, Auteur ; Gloria T. HAN, Auteur ; Julie M. WOLF, Auteur ; Adam J. NAPLES, Auteur ; Katarzyna CHAWARSKA, Auteur ; Geraldine DAWSON, Auteur ; Raphael A. BERNIER, Auteur ; Shafali S. JESTE, Auteur ; James DZIURA, Auteur ; Sara J. WEBB, Auteur ; Catherine A. SUGAR, Auteur ; Frederick SHIC, Auteur ; James C. MCPARTLAND, Auteur . - p.614-626. Langues : Anglais (eng) in Autism > 29-3 (March 2025) . - p.614-626 Index. décimale : PER Périodiques Résumé : Clinician and caregiver reports of autism features are both integral to receiving an autism diagnosis and appropriate intervention, yet informant discrepancies are present in clinical practice and may differ by demographic characteristics of the child and ... En ligne : https://dx.doi.org/10.1177/13623613241279999 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=550

Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials / Logan SHURTZ in Autism, 27-4 (May 2023)  

Public ISBD [article]  inAutism > 27-4 (May 2023) . - p.952-966 Titre : Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials Type de document : texte imprimé Auteurs : Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C. MCPARTLAND, Auteur ; April R. LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M. KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J. WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A. BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A. SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S. JESTE, Auteur Article en page(s) : p.952-966 Langues : Anglais (eng) Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499 [article] Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials [texte imprimé] / Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C. MCPARTLAND, Auteur ; April R. LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M. KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J. WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A. BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A. SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S. JESTE, Auteur . - p.952-966. Langues : Anglais (eng) in Autism > 27-4 (May 2023) . - p.952-966 Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499

Direct observation in a large-scale randomized trial of parent training in children with autism spectrum disorder and disruptive behavior / Naomi SWIEZY in Research in Autism Spectrum Disorders, 89 (November 2021)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 89 (November 2021) . - 101879 Titre : Direct observation in a large-scale randomized trial of parent training in children with autism spectrum disorder and disruptive behavior Type de document : texte imprimé Auteurs : Naomi SWIEZY, Auteur ; Tristram SMITH, Auteur ; Cindy R. JOHNSON, Auteur ; Karen E. BEARSS, Auteur ; Luc LECAVALIER, Auteur ; Rochelle DRILL, Auteur ; Danielle WARNER, Auteur ; Yanhong DENG, Auteur ; Yunshan XU, Auteur ; James DZIURA, Auteur ; Benjamin L. HANDEN, Auteur ; Lawrence SCAHILL, Auteur Article en page(s) : 101879 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder (ASD)  Direct observation  Behavioral assessment  Behavioral intervention  Randomized Control Trial (RCT)  Parent and caregiver training Index. décimale : PER Périodiques Résumé : A direct observation strategy (Standardized Observation Analogue Procedure, SOAP) was used in a large-scale randomized trial of parent training versus parent education in young children with autism spectrum disorder (ASD) and disruptive behavior. The 16-minute SOAP, modified from an earlier version of this same measure, included parentchild interaction to assess child behavior in a clinical laboratory setting. Despite study entry criteria for all child participants requiring moderate levels of disruptive behavior in this project, 126 of 168 children with complete SOAP data at baseline showed no disruptive behavior on this measure. Although the primary purpose of the study was to determine whether the SOAP could detect differences between the two conditions (i.e.,parent training (PT) and parent education (PE)), baseline observation data was not consistent with parent ratings at baseline or subsequent follow up visits, leaving little room to demonstrate improvement with this observation measure. This and the challenging, time-consuming and resource intensive effort involved in using such a measure in a large randomized scale trial, raises fundamental questions about the validity of the SOAP as an outcome measure in such a study. Further consideration related to the feasibility and practicality of using direct observation as a primary measure in larger scale efforts overall are also discussed. En ligne : https://doi.org/10.1016/j.rasd.2021.101879 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=458 [article] Direct observation in a large-scale randomized trial of parent training in children with autism spectrum disorder and disruptive behavior [texte imprimé] / Naomi SWIEZY, Auteur ; Tristram SMITH, Auteur ; Cindy R. JOHNSON, Auteur ; Karen E. BEARSS, Auteur ; Luc LECAVALIER, Auteur ; Rochelle DRILL, Auteur ; Danielle WARNER, Auteur ; Yanhong DENG, Auteur ; Yunshan XU, Auteur ; James DZIURA, Auteur ; Benjamin L. HANDEN, Auteur ; Lawrence SCAHILL, Auteur . - 101879. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 89 (November 2021) . - 101879 Mots-clés : Autism spectrum disorder (ASD)  Direct observation  Behavioral assessment  Behavioral intervention  Randomized Control Trial (RCT)  Parent and caregiver training Index. décimale : PER Périodiques Résumé : A direct observation strategy (Standardized Observation Analogue Procedure, SOAP) was used in a large-scale randomized trial of parent training versus parent education in young children with autism spectrum disorder (ASD) and disruptive behavior. The 16-minute SOAP, modified from an earlier version of this same measure, included parentchild interaction to assess child behavior in a clinical laboratory setting. Despite study entry criteria for all child participants requiring moderate levels of disruptive behavior in this project, 126 of 168 children with complete SOAP data at baseline showed no disruptive behavior on this measure. Although the primary purpose of the study was to determine whether the SOAP could detect differences between the two conditions (i.e.,parent training (PT) and parent education (PE)), baseline observation data was not consistent with parent ratings at baseline or subsequent follow up visits, leaving little room to demonstrate improvement with this observation measure. This and the challenging, time-consuming and resource intensive effort involved in using such a measure in a large randomized scale trial, raises fundamental questions about the validity of the SOAP as an outcome measure in such a study. Further consideration related to the feasibility and practicality of using direct observation as a primary measure in larger scale efforts overall are also discussed. En ligne : https://doi.org/10.1016/j.rasd.2021.101879 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=458

Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials / Susan FAJA in Autism Research, 16-5 (May 2023)  

Permalink

Face perception, attention, and memory as predictors of social change in autistic children / Sara Jane WEBB in Journal of Neurodevelopmental Disorders, 17 (2025)  

Permalink

Patterns of intervention utilization among school-aged children on the autism spectrum: Findings from a multi-site research consortium / Aksheya SRIDHAR in Research in Autism Spectrum Disorders, 94 (June 2022)  

Permalink

Sensitivity of the modified Children’s Yale–Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials / Lawrence SCAHILL in Autism, 20-2 (February 2016)  

Permalink

The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials / Frederick SHIC in Molecular Autism, 13 (2022)  

Permalink

The Selective Social Attention task in children with autism spectrum disorder: Results from the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) feasibility study / Erin C. BARNEY ; Adam J. NAPLES ; Kelsey J. DOMMER ; Shou An CHANG ; Beibin LI ; Takumi MCALLISTER ; Adham ATYABI ; Quan WANG ; Raphael A. BERNIER ; Geraldine DAWSON ; James DZIURA ; Susan FAJA ; Shafali S. JESTE ; Michael MURIAS ; Scott JOHNSON ; Maura SABATOS-DEVITO ; Gerhard HELLEMAN ; Damla SENTURK ; Catherine A. SUGAR ; Sara Jane WEBB ; James C. MCPARTLAND ; Katarzyna CHAWARSKA ; THE AUTISM BIOMARKERS CONSORTIUM FOR CLINICAL TRIALS in Autism Research, 16-11 (November 2023)  

Permalink

Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders / Lawrence SCAHILL in Journal of Autism and Developmental Disorders, 39-5 (May 2009)  

Permalink

---

1 (1 - 12 / 12) Par page : 25 50 100 200